{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:57:14Z","timestamp":1789041434970,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05394-2","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:14:52Z","timestamp":1768378492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study"],"prefix":"10.1007","volume":"176","author":[{"given":"Justyna","family":"\u017bubrowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Pieni\u0105\u017cek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polakiewicz-Gilowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Kol\u00e1\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Malej\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Ru\u0161inov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Hol\u00e1nek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"Soumarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Winsko-Szcz\u0119snowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Konieczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"M\u0142odzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Krej\u010d\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Szymanik-Resko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Ciszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Lisik-Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"P\u0119kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"\u0160ustr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Rudzi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kubeczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogumi\u0142a","family":"Czartoryska-Ar\u0142ukowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Smok-Kalwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"\u0141acko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Pacholczak-Madej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Biel\u010dikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142awa","family":"P\u00fcsk\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"11","key":"5394_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"5394_CR2","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E et al. (2024) 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). The Breast 76:103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756","journal-title":"The Breast"},{"issue":"2","key":"5394_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L (2022) Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol 19(2):91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"5394_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/annonc\/mdp407","volume":"21","author":"A Niwi\u0144ska","year":"2010","unstructured":"Niwi\u0144ska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21(5):942\u2013948. https:\/\/doi.org\/10.1093\/annonc\/mdp407","journal-title":"Ann Of Oncol"},{"issue":"23","key":"5394_CR5","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-13-0790","volume":"19","author":"NU Lin","year":"2013","unstructured":"Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS (2013) CNS metastases in breast Cancer: old challenge, New frontiers. Clin Cancer Res 19(23):6404\u20136418. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0790","journal-title":"Clin Cancer Res"},{"key":"5394_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BCTT.S274514","volume":"14","author":"A Kadamkulam Syriac","year":"2022","unstructured":"Kadamkulam Syriac A, Nandu NS, Leone JP (2022) Central nervous system metastases from triple-negative breast Cancer: current treatments and future Prospective. BCTT 14:1\u201313. https:\/\/doi.org\/10.2147\/BCTT.S274514","journal-title":"BCTT"},{"key":"5394_CR7","doi-asserted-by":"publisher","first-page":"8816102","DOI":"10.1155\/2024\/8816102","volume-title":"The breast journal","author":"E Bustamante","year":"2024","unstructured":"Bustamante E, Casas F, Luque R et al. (2024) Brain metastasis in triple-negative breast Cancer. In: Yang GJ (ed) The breast journal, vol 2024(1): p 8816102. https:\/\/doi.org\/10.1155\/2024\/8816102"},{"issue":"16","key":"5394_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al. (2021) Sacituzumab govitecan in metastatic triple-negative breast Cancer. N Engl J Med 384(16):1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"issue":"6","key":"5394_CR9","doi-asserted-by":"publisher","first-page":"188991","DOI":"10.1016\/j.bbcan.2023.188991","volume":"1878","author":"M P\u00fcsk\u00fcll\u00fco\u011flu","year":"2023","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Rudzi\u0144ska A, Pacholczak-Madej R (2023) Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis. Biochim et Biophys Acta (BBA) - Rev On Cancer 1878(6):188991. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188991","journal-title":"Biochim Et Biophys Acta (BBA) - Rev On Cancer"},{"issue":"4","key":"5394_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40487-024-00307-1","volume":"12","author":"M P\u00fcsk\u00fcll\u00fco\u011flu","year":"2024","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Pieni\u0105\u017cek M, Las-Jankowska M et al. (2024) Sacituzumab govitecan for second and subsequent line palliative treatment of patients with triple-negative breast Cancer: a Polish real-world multicenter cohort study. Oncol Ther 12(4):787\u2013801. https:\/\/doi.org\/10.1007\/s40487-024-00307-1","journal-title":"Oncol Ther"},{"issue":"5","key":"5394_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/OP.24.00242","volume":"21","author":"S Alaklabi","year":"2025","unstructured":"Alaklabi S, Roy AM, Zagami P et al. (2025) Real-world clinical outcomes with sacituzumab govitecan in metastatic triple-negative breast Cancer. JCO Oncol Pract 21(5):620\u2013628. https:\/\/doi.org\/10.1200\/OP.24.00242","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"5394_CR12","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41416-024-02685-9","volume":"130","author":"D Hanna","year":"2024","unstructured":"Hanna D, Merrick S, Ghose A et al. (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer 130(12):1916\u20131920. https:\/\/doi.org\/10.1038\/s41416-024-02685-9","journal-title":"Br J Cancer"},{"issue":"1","key":"5394_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-024-00635-5","volume":"10","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Bardia A, Punie K et al. (2024) Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer 10(1):33. https:\/\/doi.org\/10.1038\/s41523-024-00635-5","journal-title":"Npj Breast Cancer"},{"issue":"4_Supplement","key":"5394_CR14","doi-asserted-by":"publisher","first-page":"PD13","DOI":"10.1158\/1538-7445.SABCS20-PD13-07","volume":"81","author":"V Di\u00e9ras","year":"2021","unstructured":"Di\u00e9ras V, Weaver R, Tolaney SM et al. (2021) Abstract PD13-07. Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Cancer Res 81(4_Supplement):PD13\u201307. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PD13-07","journal-title":"Cancer Res"},{"issue":"1","key":"5394_CR15","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","volume":"15","author":"HU Balinda","year":"2024","unstructured":"Balinda HU, Kelly WJ, Kaklamani VG et al. (2024) Sacituzumab govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial. Nat Commun 15(1):6707. https:\/\/doi.org\/10.1038\/s41467-024-50558-9","journal-title":"Nat Commun"},{"key":"5394_CR16","unstructured":"Obwieszczenie Ministra Zdrowia z dnia 17 wrze\u015bnia 2025 r. w sprawie wykazu refundowanych lek\u00f3w, \u015brodk\u00f3w spo\u017cywczych specjalnego przeznaczenia \u017cywieniowego oraz wyrob\u00f3w medycznych na 1 pa\u017adziernika 2025 r - Ministerstwo Zdrowia - Portal Gov.pl. Ministerstwo Zdrowia. https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenie-ministra-zdrowia-z-dnia-17-wrzesnia-2025-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-pazdziernika-2025-r. Accessed December 14, 2025"},{"issue":"4","key":"5394_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","volume":"31","author":"A De Moura","year":"2024","unstructured":"De Moura A, Loirat D, Vaillant S et al. (2024) Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer 31(4):572\u2013580. https:\/\/doi.org\/10.1007\/s12282-024-01565-7","journal-title":"Breast Cancer"},{"issue":"5","key":"5394_CR18","doi-asserted-by":"publisher","first-page":"102995","DOI":"10.1016\/j.esmoop.2024.102995","volume":"9","author":"D Dannehl","year":"2024","unstructured":"Dannehl D, Jakob D, Mergel F et al. (2024) The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis. ESMO Open 9(5):102995. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102995","journal-title":"ESMO Open"},{"issue":"1","key":"5394_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-025-00736-9","volume":"11","author":"T Grinda","year":"2025","unstructured":"Grinda T, Morganti S, Hsu L et al. (2025) Real-world outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases. Npj Breast Cancer 11(1):22. https:\/\/doi.org\/10.1038\/s41523-025-00736-9","journal-title":"Npj Breast Cancer"},{"key":"5394_CR20","doi-asserted-by":"publisher","first-page":"1139372","DOI":"10.3389\/fonc.2023.1139372","volume":"13","author":"di Mauro P","year":"2023","unstructured":"di Mauro P, Schivardi G, Pedersini R et al. (2023) Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: a case report. Front Oncol 13:1139372. https:\/\/doi.org\/10.3389\/fonc.2023.1139372","journal-title":"Front Oncol"},{"issue":"12","key":"5394_CR21","doi-asserted-by":"publisher","first-page":"e7320","DOI":"10.1002\/cam4.7320","volume":"13","author":"R Weiten","year":"2024","unstructured":"Weiten R, Niemann M, Below E et al. (2024) Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer. Cancer Med 13(12):e7320. https:\/\/doi.org\/10.1002\/cam4.7320","journal-title":"Cancer Med"},{"issue":"6","key":"5394_CR22","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H et al. (2015) Response assessment criteria for brain metastases: proposal from the RANO group. The Lancet Oncol 16(6):e270\u2013e278. https:\/\/doi.org\/10.1016\/S1470-2045(15)70057-4","journal-title":"The Lancet Oncol"},{"key":"5394_CR23","doi-asserted-by":"publisher","first-page":"103309","DOI":"10.1016\/j.eclinm.2025.103309","volume":"85","author":"JM P\u00e9rez-Garc\u00eda","year":"2025","unstructured":"P\u00e9rez-Garc\u00eda JM, Gion M, Ruiz-Borrego M et al. (2025) Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial. EClinicalMedicine 85:103309. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103309","journal-title":"EClinicalMedicine"},{"key":"5394_CR24","unstructured":"SWOG Cancer Research Network (2025) A phase II trial of sacituzumab govitecan (IMMU-132) (NSC #820016) for patients with HER2-negative breast cancer and brain metastases. clinicaltrials.gov; https:\/\/clinicaltrials.gov\/study\/NCT04647916. Accessed September 6, 2025"},{"key":"5394_CR25","unstructured":"Zhang MDJ (2025) Prospective, one-arm, phase II clinical study of ivoximab combined with TROP2 ADC in the treatment of brain metastases in triple-negative breast cancer. clinicaltrials.gov; https:\/\/clinicaltrials.gov\/study\/NCT06793332. Accessed September 6, 2025"},{"key":"5394_CR26","unstructured":"Lee H (2025) Moffitt Cancer center and Research Institute. Phase I\/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases (TARGET-TNBC). clinicaltrials.gov; https:\/\/clinicaltrials.gov\/study\/NCT06238921. Accessed September 6, 2025"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05394-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:47:17Z","timestamp":1769773637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5394"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05394-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}